Access to anti-retroviral drugs, male in Lithuania

Lithuania: Access to anti-retroviral drugs, male was 50.0% in 2024. ◆ Volatile

Latest (2024)
50.0%
Change on year
up 8.7%
World rank
117th
of 141 countries
All-time high
50.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Lithuania, 2000–2024

010203040502000201220242000: 0 %2001: 0 %2002: 0 %2003: 3 %2004: 3 %2005: 4 %2006: 4 %2007: 6 %2008: 7 %2009: 8 %2010: 8 %2011: 10 %2012: 12 %2013: 18 %2014: 14 %2015: 23 %2016: 24 %2017: 29 %2018: 39 %2019: 41 %2020: 39 %2021: 39 %2022: 43 %2023: 46 %2024: 50 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Lithuania stood at 50.0%. That is the highest value across all 25 years on record.

The figure is up 8.7% on the previous year and up 257.1% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Lithuania peaked at 50.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Lithuania 117th out of 141 countries with data for 2024, putting it in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Lithuania, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Lithuania, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 3.0%
2004 3.0% +0.0%
2005 4.0% +33.3%
2006 4.0% +0.0%
2007 6.0% +50.0%
2008 7.0% +16.7%
2009 8.0% +14.3%
2010 8.0% +0.0%
2011 10.0% +25.0%
2012 12.0% +20.0%
2013 18.0% +50.0%
2014 14.0% -22.2%
2015 23.0% +64.3%
2016 24.0% +4.3%
2017 29.0% +20.8%
2018 39.0% +34.5%
2019 41.0% +5.1%
2020 39.0% -4.9%
2021 39.0% +0.0%
2022 43.0% +10.3%
2023 46.0% +7.0%
2024 50.0% +8.7%

Averages by decade

DecadeAverage LowestHighest Years
2000s 3.5% 0.0% 8.0% 10
2010s 21.8% 8.0% 41.0% 10
2020s 43.4% 39.0% 50.0% 5

Countries ranked near Lithuania

  1. 116 Latvia 51.0% compare
  2. 117 Papua New Guinea 50.0% compare
  3. 119 Libya 49.0% compare
  4. 120 Belize 48.0% compare
  5. 120 Kyrgyzstan 48.0% compare

See the full ranking of 160 places →

More gender data for Lithuania

All data for Lithuania →

Frequently asked questions

What is access to anti-retroviral drugs, male in Lithuania?
Access to anti-retroviral drugs, male in Lithuania was 50.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Lithuania?
The highest recorded value was 50.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Lithuania?
The lowest recorded value was 0.0% in 2000.
How does Lithuania rank for access to anti-retroviral drugs, male?
Lithuania ranks 117th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Lithuania?
Over the last ten years it is up 257.1%. The long-run trend across the full record is volatile.
Where does this Lithuania data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Lithuania. Statizoid, drawing on UNAIDS estimates. Retrieved 06 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/lithuania/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/lithuania/">Access to anti-retroviral drugs, male in Lithuania</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.